Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 5:21 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–187 of 187 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: PARP Inhibitor Clear all

Conditions: BRCA1 Mutation Carrier, BRCA2 Mutation Carrier, Endometrial Adenocarcinoma, Estrogen Receptor Negative, HER2/Neu Negative, High Grade Ovarian Serous Adenocarcinoma, Progesterone Receptor Negative, Recurrent Breast Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Recurrent Uterine Corpus Carcinoma, Stage III Uterine Corpus Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7, Stage IV Uterine Corpus Cancer AJCC v7, Triple-Negative Breast Carcinoma
Interventions: Capivasertib, Laboratory Biomarker Analysis, Olaparib, Pharmacological Study, Vistusertib; Drug · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 159 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Ovarian Carcinoma
Interventions: Biospecimen Collection, Laboratory Biomarker Analysis, Medical Chart Review; Procedure · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: Female only
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Ovarian Neoplasm
Interventions: Dostarlimab, Bevacizumab, Niraparib; Drug
Lead sponsor: Tesaro, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 10
States / cities: Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 6 more

Conditions: Pancreatic Adenocarcinoma Metastatic
Interventions: Niraparib, FOLFIRI, Ipilimumab; Drug
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 2
States / cities: Boston, Massachusetts • Philadelphia, Pennsylvania

Conditions: Advanced Solid Tumor, Ovarian Cancer, Ovary Cancer, Cancer of Ovary, Cancer of the Ovary, Ovary Neoplasm, Pancreatic Cancer, Pancreas Cancer, Cancer of Pancreas, Cancer of the Pancreas, Pancreas Neoplasm, Prostate Cancer, Prostatic Cancer, Cancer of Prostate, Cancer of the Prostate, Prostate Neoplasm, Castrate Resistant Prostate Cancer, Castration Resistant Prostatic Cancer, Castration Resistant Prostatic Neoplasms, Triple-negative Breast Cancer, Triple Negative Breast Cancer, Triple Negative Breast Neoplasms, Breast Cancer, Breast Carcinoma, Cancer of Breast, Cancer of the Breast, Breast Tumor
Interventions: NUV-868, Olaparib, Enzalutamide; Drug
Lead sponsor: Nuvation Bio Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 17
States / cities: Tucson, Arizona • Los Angeles, California • Aurora, Colorado + 13 more

Conditions: Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
Interventions: Rucaparib, Placebo; Drug
Lead sponsor: pharmaand GmbH; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 564 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2022
U.S. locations: 22
States / cities: Tucson, Arizona • Fullerton, California • Sacramento, California + 18 more

Conditions: Advanced Breast Cancer, HER2/Neu Negative, Triple-Negative Breast Cancer
Interventions: Talazoparib Tosylate; Drug
Lead sponsor: Melinda Telli; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 1
States / cities: Stanford, California

Conditions: Breast Cancer, Triple Negative Breast Cancer
Interventions: Niraparib, Dostarlimab, Radiation therapy; Drug · Radiation
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 4
States / cities: Washington D.C., District of Columbia • Boston, Massachusetts • Durham, North Carolina + 1 more

Conditions: Breast Neoplasms, BRCA 1 Gene Mutation, BRCA 2 Gene Mutation
Interventions: talazoparib; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 37
States / cities: Greenbrae, California • Los Angeles, California • Palo Alto, California + 19 more

Conditions: Human Volunteers
Interventions: BMN 673; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Evansville, Indiana

Conditions: Ovarian Neoplasms, Ovarian Cancer
Interventions: Niraparib; Drug
Lead sponsor: Tesaro, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 463 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 48
States / cities: Chandler, Arizona • Phoenix, Arizona • Tucson, Arizona + 41 more

Conditions: Ovarian Neoplasms
Interventions: AZD2281, Liposomal Doxorubicin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years · Female only
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2018
U.S. locations: 6
States / cities: Los Angeles, California • San Francisco, California • Boca Raton, Florida + 3 more

Conditions: Pancreatic Neoplasms
Interventions: KU-0059436 (AZD2281)(PARP inhibitor), Gemcitabine; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 2
States / cities: New York, New York • Nashville, Tennessee

Conditions: Neoplasms
Interventions: AZD 2281, Cisplatin, Gemcitabine; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Ovarian Neoplasms
Interventions: Niraparib, Bevacizumab; Drug · Biological
Lead sponsor: Tesaro, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 29
States / cities: Mobile, Alabama • Anchorage, Alaska • Mesa, Arizona + 25 more

Conditions: Advanced Solid Tumor
Interventions: M9466, Irinotecan, Folinic acid, Fluorouracil (5-FU), Bevacizumab, Granulocyte colony stimulating factor (G-CSF); Drug
Lead sponsor: EMD Serono Research & Development Institute, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 4
States / cities: Denver, Colorado • Pennington, New Jersey • Nashville, Tennessee + 1 more

Conditions: Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma
Interventions: Rucaparib; Drug
Lead sponsor: pharmaand GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 5
States / cities: Los Angeles, California • Rochester, Minnesota • New York, New York + 2 more

Conditions: Ovarian Cancer
Interventions: NMS-03305293, Topotecan; Drug
Lead sponsor: Nerviano Medical Sciences; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 5
States / cities: Peoria, Illinois • St Louis, Missouri • Philadelphia, Pennsylvania + 2 more

Conditions: Metastatic Prostate Cancer
Interventions: Enzalutamide, Niraparib; Drug
Lead sponsor: Paul Mathew, MD; Other
Eligibility: 18 Years and older · Male only
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Search by objective public record fields.

mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian

Metabolite Levels in Ovarian Cancer Patients Receiving Maintenance PARP Inhibitors

Study to Evaluate the Safety and Efficacy of TSR-042, Bevacizumab, and Niraparib in Participants With Recurrent Ovarian Cancer

Maintenance Niraparib Plus Ipilimumab in Patients With Metastatic Pancreatic Adenocarcinoma Whose Disease Has Not Progressed on Platinum-Based Chemotherapy

NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors

Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous or Endometrioid Ovarian Cancer (ARIEL3)

Phase II Trial of Talazoparib in BRCA1/2 Wild-type HER2-negative Breast Cancer and Other Solid Tumors

Radiation, Immunotherapy and PARP Inhibitor in Triple Negative Breast Cancer

A Phase 2, 2-Stage, 2-Cohort Study of Talazoparib (BMN 673), in Locally Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (ABRAZO Study)

Study of BMN 673, a PARP Inhibitor, in Healthy Adult Male Volunteers

A Study of Niraparib in Patients With Ovarian Cancer Who Have Received Three or Four Previous Chemotherapy Regimens

Dose-finding Study Comparing Efficacy and Safety of a PARP Inhibitor Against Doxil in BRCA+ve Advanced Ovarian Cancer

Study to Assess the Safety & Tolerability of a PARP Inhibitor in Combination With Gemcitabine in Pancreatic Cancer

AZD2281 and Cisplatin Plus Gemcitabine to Treat Solid Tumor Cancers

A Study of Niraparib Combined With Bevacizumab Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

M9466 in Combination With Topoisomerase 1 Inhibitors-based Regimens in Advanced Solid Tumors and Colorectal Cancer (DDRiver 511)

A Study of Rucaparib in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation

Study of NMS-03305293 in Adult Patients With Relapsed Ovarian Cancer

Enzalutamide and Niraparib in the Treatment of Metastatic Castrate-Resistant Prostate Cancer (CRPC)